{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T02:27:17Z","timestamp":1769912837590,"version":"3.49.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T00:00:00Z","timestamp":1699574400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T00:00:00Z","timestamp":1699574400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1007\/s00467-023-06187-3","type":"journal-article","created":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T16:02:28Z","timestamp":1699632148000},"page":"1149-1160","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Intravenous cyclophosphamide therapy in children with calcineurin inhibitor-resistant steroid-resistant nephrotic syndrome in a resource-limited setting"],"prefix":"10.1007","volume":"39","author":[{"given":"Paraselli","family":"Saiteja","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bobbity","family":"Deepthi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sudarsan","family":"Krishnasamy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madhileti","family":"Sravani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0121-1486","authenticated-orcid":false,"given":"Sriram","family":"Krishnamurthy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,11,10]]},"reference":[{"key":"6187_CR1","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1007\/s13312-021-2262-y","volume":"58","author":"A Vasudevan","year":"2021","unstructured":"Vasudevan A, Thergaonkar R, Mantan M, Sharma J, Khandelwal P, Hari P, Expert Group of the Indian Society of Pediatric Nephrology et al (2021) Consensus guidelines on management of steroid-resistant nephrotic syndrome. Indian Pediatr 58:650\u2013666","journal-title":"Indian Pediatr"},{"key":"6187_CR2","doi-asserted-by":"publisher","first-page":"41","DOI":"10.4103\/0971-4065.107197","volume":"23","author":"A Sinha","year":"2013","unstructured":"Sinha A, Sharma A, Mehta A, Gupta R, Gulati A, Hari P et al (2013) Calcineurin inhibitor induced nephrotoxicity in steroid resistant nephrotic syndrome. Indian J Nephrol 23:41\u201346","journal-title":"Indian J Nephrol"},{"key":"6187_CR3","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1007\/s00467-008-0860-8","volume":"23","author":"M Mantan","year":"2008","unstructured":"Mantan M, Sriram CS, Hari P, Dinda A, Bagga A (2008) Efficacy of intravenous pulse cyclophosphamide treatment versus combination of intravenous dexamethasone and oral cyclophosphamide treatment in steroid-resistant nephrotic syndrome. Pediatr Nephrol 23:1495\u20131502","journal-title":"Pediatr Nephrol"},{"key":"6187_CR4","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1007\/s00467-008-0794-1","volume":"23","author":"C Plank","year":"2008","unstructured":"Plank C, Kalb V, Hinkes B, Hildebrandt F, Gefeller O, Rascher W, Arbeitsgemeinschaft f\u00fcr P\u00e4diatrische Nephrologie (2008) Cyclosporin A is superior to cyclophosphamide in children with steroid-resistant nephrotic syndrome-a randomized controlled multicentre trial by the Arbeitsgemeinschaft f\u00fcr P\u00e4diatrische Nephrologie. Pediatr Nephrol 23:1483\u20131493","journal-title":"Pediatr Nephrol"},{"key":"6187_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/BF00868243","volume":"8","author":"R Elhence","year":"1994","unstructured":"Elhence R, Gulati S, Kher V, Gupta A, Sharma RK (1994) Intravenous pulse cyclophosphamide-a new regime for steroid-resistant minimal change nephrotic syndrome. Pediatr Nephrol 8:1\u20133","journal-title":"Pediatr Nephrol"},{"key":"6187_CR6","first-page":"CD 003594","volume":"2019","author":"ID Liu","year":"2019","unstructured":"Liu ID, Willis NS, Craig JC, Hodson EM (2019) Interventions for idiopathic steroid-resistant nephrotic syndrome in children. Cochrane Database Syst Rev 2019:CD 003594","journal-title":"Cochrane Database Syst Rev"},{"key":"6187_CR7","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1038\/ki.2012.238","volume":"82","author":"A Gulati","year":"2012","unstructured":"Gulati A, Sinha A, Gupta A, Kanitkar M, Sreenivas V, Sharma J et al (2012) Treatment with tacrolimus and prednisolone is preferable to intravenous cyclophosphamide as the initial therapy for children with steroid-resistant nephrotic syndrome. Kidney Int 82:1130\u20131135","journal-title":"Kidney Int"},{"key":"6187_CR8","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1093\/ndt\/gfu267","volume":"30","author":"A Sinha","year":"2015","unstructured":"Sinha A, Bhatia D, Gulati A, Rawat M, Dinda AK, Hari P, Bagga A (2015) Efficacy and safety of rituximab in children with difficult-to-treat nephrotic syndrome. Nephrol Dial Transplant 30:96\u2013106","journal-title":"Nephrol Dial Transplant"},{"key":"6187_CR9","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jpeds.2018.01.008","volume":"197","author":"M Jellouli","year":"2018","unstructured":"Jellouli M, Charfi R, Maalej B, Mahfoud A, Trabelsi S, Gargah T (2018) Rituximab in the management of pediatric steroid-resistant nephrotic syndrome: a systematic review. J Pediatr 197:191\u2013197","journal-title":"J Pediatr"},{"key":"6187_CR10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s00467-018-4166-1","volume":"35","author":"K Kamei","year":"2020","unstructured":"Kamei K, Ishikura K, Sako M, Ito S, Nozu K, Iijima K (2020) Rituximab therapy for refractory steroid-resistant nephrotic syndrome in children. Pediatr Nephrol 35:17\u201324","journal-title":"Pediatr Nephrol"},{"key":"6187_CR11","doi-asserted-by":"publisher","first-page":"3055","DOI":"10.1681\/ASN.2016101121","volume":"28","author":"A Trautmann","year":"2017","unstructured":"Trautmann A, Schnaidt S, Lipska-Zi\u0119tkiewicz BS, Bodria M, Ozaltin F, Emma F, PodoNet Consortium et al (2017) Long-term outcome of steroid-resistant nephrotic syndrome in children. J Am Soc Nephrol 28:3055\u20133065","journal-title":"J Am Soc Nephrol"},{"key":"6187_CR12","doi-asserted-by":"publisher","first-page":"203","DOI":"10.5301\/JN.2011.6327","volume":"24","author":"TT Gargah","year":"2011","unstructured":"Gargah TT, Lakhoua MR (2011) Mycophenolate mofetil in treatment of childhood steroid-resistant nephrotic syndrome. J Nephrol 24:203\u2013207","journal-title":"J Nephrol"},{"key":"6187_CR13","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1007\/s00467-020-04519-1","volume":"35","author":"A Trautmann","year":"2020","unstructured":"Trautmann A, Vivarelli M, Samuel S, Gipson D, Sinha A, Schaefer F, International Pediatric Nephrology Association et al (2020) IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome. Pediatr Nephrol 35:1529\u20131561","journal-title":"Pediatr Nephrol"},{"key":"6187_CR14","first-page":"203","volume":"45","author":"A Bagga","year":"2008","unstructured":"Bagga A, Ali U, Banerjee S, Kanitkar M, Phadke KD, Senguttuvan P, Sethi S, Shah M, Indian Pediatric Nephrology Group, Indian Academy of Pediatrics (2008) Management of steroid sensitive nephrotic syndrome: revised guidelines. Indian Pediatr 45:203\u2013214","journal-title":"Indian Pediatr"},{"key":"6187_CR15","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1007\/s00467-002-0896-0","volume":"17","author":"VK Sairam","year":"2002","unstructured":"Sairam VK, Kalia A, Rajaraman S, Travis LB (2002) Secondary resistance to cyclosporin A in children with nephrotic syndrome. Pediatr Nephrol 17:842\u2013846","journal-title":"Pediatr Nephrol"},{"key":"6187_CR16","doi-asserted-by":"publisher","first-page":"313","DOI":"10.3389\/fped.2019.00313","volume":"7","author":"R Topaloglu","year":"2019","unstructured":"Topaloglu R, Gulhan B, Celegen K, Inozu M, Hayran M, Duzova A et al (2019) Rituximab for children with difficult-to-treat nephrotic syndrome: its effects on disease progression and growth. Front Pediatr 7:313","journal-title":"Front Pediatr"},{"key":"6187_CR17","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1681\/ASN.2011080775","volume":"23","author":"A Magnasco","year":"2012","unstructured":"Magnasco A, Ravani P, Edefonti A, Murer L, Ghio L, Belingheri M et al (2012) Rituximab in children with resistant idiopathic nephrotic syndrome. J Am Soc Nephrol 23:1117\u20131124","journal-title":"J Am Soc Nephrol"},{"key":"6187_CR18","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1681\/ASN.2012040413","volume":"23","author":"M Pradhan","year":"2012","unstructured":"Pradhan M, Furth S (2012) Rituximab in steroid-resistant nephrotic syndrome in children: a (false) glimmer of hope? J Am Soc Nephrol 23:975\u2013978","journal-title":"J Am Soc Nephrol"},{"key":"6187_CR19","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1007\/s00467-009-1195-9","volume":"24","author":"MC Chaumais","year":"2009","unstructured":"Chaumais MC, Garnier A, Chalard F, Peuchmaur M, Dauger S, Jacqz-Agrain E et al (2009) Fatal pulmonary fibrosis after rituximab administration. Pediatr Nephrol 24:1753\u20131755","journal-title":"Pediatr Nephrol"},{"key":"6187_CR20","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1080\/08860220500198623","volume":"27","author":"K El-Reshaid","year":"2005","unstructured":"El-Reshaid K, El-Reshaid W, Madda J (2005) Combination of immunosuppressive agents in treatment of steroid-resistant minimal change disease and primary focal segmental glomerulosclerosis. Ren Fail 27:523\u2013530","journal-title":"Ren Fail"},{"key":"6187_CR21","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/nep.12351","volume":"20","author":"B Wu","year":"2015","unstructured":"Wu B, Mao J, Shen H, Fu H, Wang J, Liu A et al (2015) Triple immunosuppressive therapy in steroid-resistant nephrotic syndrome children with tacrolimus resistance or tacrolimus sensitivity but frequently relapsing. Nephrology 20:18\u201324","journal-title":"Nephrology"},{"key":"6187_CR22","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1007\/s00467-020-04481-y","volume":"35","author":"P Ravani","year":"2020","unstructured":"Ravani P, Pisani I, Bodria M, Caridi G, Degl\u2019Innocenti ML, Ghiggeri GM (2020) Low-dose ofatumumab for multidrug-resistant nephrotic syndrome in children: a randomized placebo-controlled trial. Pediatr Nephrol 35:997\u20131003","journal-title":"Pediatr Nephrol"},{"key":"6187_CR23","doi-asserted-by":"publisher","first-page":"e00267","DOI":"10.1002\/prp2.267","volume":"5","author":"A Bonanni","year":"2017","unstructured":"Bonanni A, Bertelli E, Panicucci C, D\u2019Alessandro M, Moscatelli A, Lampugnani E et al (2017) Ofatumumab-associated acute pneumonitis: not new but still the first case. Pharmacol Res Perspect 5:e00267","journal-title":"Pharmacol Res Perspect"},{"key":"6187_CR24","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.kint.2021.05.015","volume":"100","author":"BH Rovin","year":"2021","unstructured":"Rovin BH, Adler SG, Barratt J, Bridoux F, Burdge KA, Chan TM et al (2021) Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. Kidney Int 100:753\u2013779","journal-title":"Kidney Int"},{"key":"6187_CR25","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1007\/s00467-006-0276-2","volume":"21","author":"R Bhimma","year":"2006","unstructured":"Bhimma R, Adhikari M, Asharam K (2006) Steroid-resistant nephrotic syndrome: the influence of race on cyclophosphamide sensitivity. Pediatr Nephrol 21:1847\u20131853","journal-title":"Pediatr Nephrol"},{"key":"6187_CR26","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s00467-003-1095-3","volume":"18","author":"A Bajpai","year":"2003","unstructured":"Bajpai A, Bagga A, Hari P, Dinda A, Srivastava RN (2003) Intravenous cyclophosphamide in steroid-resistant nephrotic syndrome. Pediatr Nephrol 18:351\u2013356","journal-title":"Pediatr Nephrol"},{"key":"6187_CR27","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1186\/s12882-021-02605-6","volume":"22","author":"M Haddad","year":"2021","unstructured":"Haddad M, Kale A, Butani L (2021) Intravenous cyclophosphamide induces remission in children with difficult to treat steroid resistant nephrotic syndrome from minimal change disease. BMC Nephrol 22:395","journal-title":"BMC Nephrol"},{"key":"6187_CR28","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1016\/j.clinthera.2012.03.008","volume":"34","author":"H Li","year":"2012","unstructured":"Li H, Shi X, Shen H, Li X, Wang H, Li H et al (2012) Tacrolimus versus intravenous pulse cyclophosphamide therapy in Chinese adults with steroid-resistant idiopathic minimal change nephropathy: a multicenter, open-label, nonrandomized cohort trial. Clin Ther 34:1112\u20131120","journal-title":"Clin Ther"},{"key":"6187_CR29","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/BF00860726","volume":"9","author":"LC Hymes","year":"1995","unstructured":"Hymes LC (1995) Steroid-resistant, cyclosporin-responsive, relapsing nephrotic syndrome. Pediatr Nephrol 9:137\u2013139","journal-title":"Pediatr Nephrol"},{"key":"6187_CR30","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1038\/ki.1993.194","volume":"43","author":"C Ponticelli","year":"1993","unstructured":"Ponticelli C, Rizzoni G, Edefonti A, Altieri P, Rivolta E, Rinaldi S, Ghio L, Lusvarghi E, Gusmano R, Locatelli F, Pasquali S, Castellani A, Della Casa-Alberighi OD (1993) A randomized trial of cyclosporine in steroid resistant idiopathic nephrotic syndrome. Kidney Int 43:1377\u20131384","journal-title":"Kidney Int"},{"key":"6187_CR31","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1007\/BF00853590","volume":"1","author":"P Niaudet","year":"1987","unstructured":"Niaudet P, Habib R, Tete MJ, Hinglais N, Broyer M (1987) Cyclosporin in the treatment of idiopathic nephrotic syndrome in children. Pediatr Nephrol 1:566\u2013573","journal-title":"Pediatr Nephrol"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-023-06187-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-023-06187-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-023-06187-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T10:06:25Z","timestamp":1709028385000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-023-06187-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,10]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["6187"],"URL":"https:\/\/doi.org\/10.1007\/s00467-023-06187-3","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,10]]},"assertion":[{"value":"8 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Approved by the Ethics Committee of the institute (IEC\/2021\/111 dated 19 July 2021).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors affirm that human research participants provided informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors affirm that human research participants provided informed consent for publication of the images if applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article. The authors have no financial or proprietary interests in any material discussed in this article.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}